This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of fingolimod
MSMED_FINGOLIMOD
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
349 |
4. Check minimum number of events
Min. number of events
3
|
349 |
5. Include endpointsNone |
349 |
6. Filter based on genotype QC (FinnGen only) |
329 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of fingolimod
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- L04AA Selective immunosuppressants
- Other degenerative diseases of the nervous system
- ILD medications: immunosuppressive drugs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 329 | 267 | 62 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.03 |
| Median age at first event (years) | 38.53 | 38.21 | 39.94 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 349
- Matched controls
- 3490
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L03AB07
ATC
interferon beta-1a; parenteral
461.7
307.7
199
10
164
Kela drug reimbursment
Fingolimod
+∞
307.7
349
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
1116.1
307.7
295
17
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
907.8
307.7
293
20
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
53.4
307.7
258
176
109
Kela drug reimbursment
Multiple sclerosis
12675.8
307.7
346
20
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
349
31
353
Kela drug reimbursment
Cladribine and fingolimod
7944.7
307.7
312
*
L04AA27
ATC
[U] fingolimod
+∞
307.7
349
*
H46
ICD-10 Finland
Optic neuritis
124.8
283.0
146
20
L03AX13
ATC
glatiramer acetate; parenteral
472.9
201.0
183
8
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
77.5
189.7
104
19
N86
ICPC
Multiple sclerosis
718.4
173.0
157
*
L04AE01
ATC
fingolimod; oral
+∞
152.6
135
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
45.6
152.6
94
28
Z01.0
ICD-10 Finland
Examination of eyes and vision
15.0
151.0
201
289
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
49.1
133.6
80
21
M03BX01
ATC
baclofen; systemic
35.9
132.0
87
32
L03AB08
ATC
interferon beta-1b; parenteral
1595.2
120.2
110
*
ZX120
NOMESCO Finland
Intravenous
14.5
110.2
118
119
G04BD12
ATC
mirabegron; oral
15.9
103.7
101
87
XKD00
NOMESCO Finland
Uroflowmetry
18.4
98.1
86
61
N04BB01
ATC
amantadine; oral
150.7
95.8
98
9
XCK00
NOMESCO Finland
Perimetry
17.9
92.7
82
59
TAB00
NOMESCO Finland
Lumbar puncture
13.5
87.8
94
93
XCW99
NOMESCO Finland
Other investigative procedure of eye
12.0
87.1
103
118
XKD06
NOMESCO Finland
Physiologic investigation of micturition
31.4
86.0
58
22
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.8
80.7
114
164
H02AB04
ATC
methylprednisolone; systemic
8.5
79.9
136
243
XA800
NOMESCO Finland
Neuropsychological investigation
12.7
73.7
80
80
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
17.2
72.6
64
45
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
16.5
69.1
62
45
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
10.7
61.8
75
87
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
22.9
61.0
46
23
G04BD08
ATC
solifenacin; oral
16.1
61.0
55
40
2AB04, ,
NOMESCO Finland
147.2
59.0
61
5
L04AA31
ATC
[U] teriflunomide
221.5
55.8
56
*
XKC03
NOMESCO Finland
Water cystometry
18.8
55.7
46
28
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
10.2
47.5
58
67
4AA23, ,
NOMESCO Finland
524.5
47.5
46
*
UKC02
NOMESCO Finland
Cystoscopy
7.4
47.1
78
130
L04AX07
ATC
dimethyl fumarate; oral
67.6
45.8
52
9
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
15.4
44.1
40
29
G04BD09
ATC
trospium; oral
79.1
43.3
48
7
H53.2
ICD-10 Finland
Diplopia
13.9
42.5
41
33
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
7.9
41.9
64
97
N06BA07
ATC
modafinil; oral
75.3
41.2
46
7
R1250
NOMESCO Finland
Evaluation of functional capability
13.6
40.9
40
33
N07XX09
ATC
[U] dimethyl fumarate
83.4
40.0
44
6
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
408.7
37.8
37
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
13.7
37.2
36
29
G04BD07
ATC
tolterodine; oral
13.3
35.5
35
29
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.7
34.6
75
161
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
367.3
33.5
33
*
N05CF01
ATC
zopiclone; oral
3.8
32.4
155
607
N03AX12
ATC
[U] gabapentin; oral
4.4
32.2
103
304
Z3226
NOMESCO Finland
Physiotherapist
4.3
31.9
107
327
R35
ICD-10 Finland
Polyuria
7.6
31.0
47
70
C10AC01
ATC
colestyramine; oral
10.7
29.9
34
35
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
113.1
29.2
31
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.0
27.5
53
101
SPAT1229
SPAT
Assessment of need for aid
8.6
26.9
36
46
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
11.2
26.6
29
28
Z3229
NOMESCO Finland
Other healthcare associate professional
6.1
26.1
49
91
R20.2
ICD-10 Finland
Paraesthesia of skin
4.7
25.5
68
172
N03AE01
ATC
clonazepam; systemic
6.1
24.5
46
85
TKC22
NOMESCO Finland
Catheterisation instruction
40.8
24.4
30
8
L04AG12
ATC
ofatumumab; parenteral
245.4
22.9
23
*
N03AX16
ATC
[U] pregabalin
3.3
22.2
113
444
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
222.7
20.8
21
*
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
61.3
20.1
23
*
G04CA01
ATC
alfuzosin; oral
6.9
20.0
32
50
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
20.0
19
*
XCK10
NOMESCO Finland
Photography of fundus of eye
4.9
19.8
47
107
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
111.4
19.8
21
*
N02BF01
ATC
gabapentin; oral
4.5
19.6
52
130
Z2445
NOMESCO Finland
Psychologist
5.0
19.5
45
100
L28
ICPC
Limited function/disability (L)
4.1
19.3
60
169
SPAT1215
SPAT
Assessment of need for medical rehabilitation
6.5
18.9
32
53
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
3.0
18.9
112
475
J01EA01
ATC
trimethoprim; systemic
2.9
18.9
131
606
R4110
NOMESCO Finland
Physiotherapy
2.9
18.8
119
523
Z3231
NOMESCO Finland
Registered nurse
2.9
18.8
127
579
G04BD04
ATC
oxybutynin; oral, transdermal
6.6
18.4
31
51
R4120
NOMESCO Finland
Occupational therapy
4.6
17.9
46
112
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
17.9
17
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
39.0
17.8
22
6
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
16.8
17.8
28
18
A02BC02
ATC
pantoprazole; systemic
2.9
17.6
256
1700
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
7.6
17.2
25
35
L04AA40
ATC
cladribine; oral
66.7
16.9
19
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
4.9
16.3
38
85
RF120, ,
NOMESCO Finland
31.8
16.3
21
7
XKD03
NOMESCO Finland
Urethral pressure profilometry
19.7
16.2
24
13
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.3
16.1
70
246
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
15.7
139
714
L03AB13
ATC
peginterferon beta-1a; parenteral
167.2
15.6
16
*
R5110, ,
SPAT
5.9
15.5
29
53
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.4
15.2
40
99
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
26.4
14.9
20
8
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.9
14.5
27
49
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.2
14.5
64
226
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
31.5
14.0
18
6
XCD10
NOMESCO Finland
Electrophysiological examination of eye
11.1
14.0
26
25
G04CA02
ATC
tamsulosin; oral
4.6
14.0
35
83
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.7
13.6
33
76
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
145.4
13.5
14
*
G04BD11
ATC
fesoterodine; oral
19.2
13.5
20
11
RF420, ,
NOMESCO Finland
20.0
13.1
19
10
N06AX16
ATC
venlafaxine; oral
2.6
13.0
91
413
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
33.4
12.7
16
5
L01BB04
ATC
cladribine; systemic
+∞
12.6
12
*
R4150
NOMESCO Finland
Neuropsychological rehabilitation
13.1
12.3
21
17
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
6.3
12.3
21
35
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
27.8
12.2
16
6
A28
ICPC
Limited function/disability NOS
3.9
12.1
37
102
RF410, ,
NOMESCO Finland
22.2
12.1
17
8
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
19.8
11.7
17
9
N29
ICPC
Neurological sympt/complt other
9.7
11.2
22
24
Z50.1
ICD-10 Finland
Other physical therapy
5.2
10.9
23
47
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.5
10.8
27
64
H02AB06
ATC
prednisolone; systemic
2.1
10.3
170
1090
U13
ICPC
Bladder symptom/complaint other
8.3
10.3
22
28
R33
ICD-10 Finland
Retention of urine
5.3
10.2
21
42
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
41.3
10.0
12
*
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
9.6
87
439
N30.0
ICD-10 Finland
Acute cystitis
2.4
9.4
76
364
Z2446
NOMESCO Finland
Social worker
3.2
9.0
38
130
A06AD11
ATC
lactulose; oral
3.2
8.9
37
125
R15
ICD-10 Finland
Faecal incontinence
9.9
8.9
17
18
G51.0
ICD-10 Finland
Bell palsy
7.2
8.7
20
29
J05AB11
ATC
valaciclovir; oral
2.4
8.5
69
330
359
Kela drug reimbursment
Mirabegroni
92.2
8.4
9
*
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
13.2
8.4
14
11
WW400
NOMESCO Finland
Plasmaferesis
+∞
8.4
8
*
G04BE03
ATC
sildenafil; oral
+∞
8.4
8
*
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
+∞
8.4
8
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
+∞
8.4
8
*
RS340, ,
NOMESCO Finland
+∞
8.4
8
*
U01
ICPC
Dysuria/painful urination
3.0
8.2
37
131
R42
ICD-10 Finland
Dizziness and giddiness
2.3
8.2
67
321
OAB50, ,
SPAT
4.2
8.2
22
55
J05AB01
ATC
aciclovir; systemic
2.1
8.2
100
565
J01CA08
ATC
pivmecillinam; oral
1.9
8.1
186
1302
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
22.6
8.1
11
5
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.7
8.0
26
75
TKC20
NOMESCO Finland
Catheterisation of bladder
4.0
7.9
23
61
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
4.0
7.9
23
61
H53.1
ICD-10 Finland
Subjective visual disturbances
3.0
7.9
36
129
H47.2
ICD-10 Finland
Optic atrophy
46.0
7.7
9
*
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
13.8
7.4
12
9
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
7.3
7
*
N04BD01
ATC
selegiline; oral
16.2
7.3
11
7
N28
ICPC
Limited function/disability (N)
12.4
7.1
12
10
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
7.0
42
174
TPH04
NOMESCO Finland
Cathetrisation of vein
2.1
6.9
70
365
N30.9
ICD-10 Finland
Cystitis, unspecified
3.1
6.9
29
99
RS222, ,
NOMESCO Finland
11.2
6.8
12
11
N03AF01
ATC
carbamazepine; oral, rectal
3.7
6.8
22
63
J01AA02
ATC
doxycycline; systemic
2.0
6.7
269
2194
RS221, ,
NOMESCO Finland
8.1
6.7
14
18
N99
ICPC
Neurological disease other
12.6
6.6
11
9
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
4.1
6.5
18
46
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
71.1
6.4
7
*
SPAT1216
SPAT
Assessment of functional ability
2.7
6.4
34
132
SPAT1325
SPAT
Vaccination
1.9
6.4
95
569
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
6.3
6
*
4AA36, ,
NOMESCO Finland
+∞
6.3
6
*
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
27.2
6.3
8
*
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.7
6.2
33
128
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
136
59
37.13
198.47
1.2
1.1
—
—
—
0
0
90
8
150.92
87.79
2.9
2.6
—
—
—
0
0
126
195
9.55
84.26
4.6
2.0
9.06
10.20
g/l
3.77
120
181
52
17
35.77
80.70
2.1
2.9
—
—
—
0
0
337
1619
32.45
70.31
20.4
8.3
3.36
3.94
e9/l
11.02
332
1430
220
738
6.36
65.41
7.3
2.6
—
—
—
0
0
186
555
6.03
62.65
5.7
2.3
0.09
0.24
e6/l
1.53
165
401
62
59
12.56
58.49
6.0
3.9
67.45
56.39
%
9.51
62
59
62
59
12.56
58.49
5.9
3.7
3.36
4.02
e9/l
1.65
62
59
52
41
14.73
54.95
1.2
1.1
—
—
—
0
0
272
1221
6.56
54.38
6.8
5.2
9.67
9.50
umol/l
0.19
264
1156
110
312
4.69
36.61
4.8
2.1
0.88
0.77
e6/l
0.11
63
160
39
7
62.45
34.01
1.2
1.0
—
—
—
0
0
294
1762
5.24
32.44
10.8
3.5
45.33
966.29
e6/l
—
6
14
101
303
4.28
30.73
5.0
2.1
6.31
4.11
e6/l
0.39
53
151
221
1136
3.58
29.42
2.5
2.3
97.92
72.69
nmol/l
21.68
212
1083
244
1385
3.53
26.64
7.8
2.8
0.00
0.00
estimate
-0.00
74
257
241
1364
3.48
26.30
9.7
3.9
0.00
0.00
estimate
0.50
73
266
241
1375
3.43
25.72
7.9
2.8
0.00
0.00
estimate
-0.00
76
277
56
130
4.94
23.21
1.5
1.4
—
—
—
0
0
32
17
20.57
21.71
1.3
1.1
1654.94
1558.18
miu/ml
0.15
32
17
21
5
44.58
17.48
1.1
1.2
—
—
—
0
0
82
307
3.18
17.04
2.7
2.1
72.70
2764.48
u/l
2.84
20
128
20
5
42.31
16.51
1.6
4.0
—
—
—
0
0
180
1078
2.38
14.18
9.0
2.7
—
—
—
0
0
24
20
12.79
13.81
1.0
1.1
—
—
—
0
0
30
68
4.73
12.64
1.2
1.7
12.61
4.56
e6/l
1.49
23
52
30
68
4.73
12.64
1.3
1.7
0.88
132.16
e6/l
0.96
24
55
127
687
2.33
12.25
11.0
3.0
0.00
0.01
estimate
1.08
72
264
23
24
10.18
11.93
1.1
1.1
54.75
31.94
mg/l
1.35
16
19
19
20
9.98
9.89
3.0
3.0
48.21
44.73
%
—
14
9
58
240
2.70
9.75
3.2
1.6
—
—
—
0
0
21
33
6.70
8.62
1.0
1.1
—
—
—
0
0
20
33
6.36
7.97
1.0
1.2
—
—
—
0
0
225
2723
0.51
7.80
2.8
3.0
1.24
1.23
mmol/l
0.04
214
2607
238
2826
0.50
7.67
2.9
3.2
1.52
1.48
mmol/l
0.70
225
2721
19
31
6.42
7.65
1.0
1.2
—
—
—
0
0
13
13
10.33
7.09
6.6
1.5
—
—
—
0
0
243
2849
0.52
7.01
3.0
3.4
3.04
2.94
mmol/l
1.02
227
2736
241
2832
0.52
6.98
2.9
3.3
4.94
4.82
mmol/l
1.27
229
2731
271
2224
1.98
6.56
5.9
2.8
55.03
35.11
u/l
5.30
266
2151
243
1955
1.80
5.89
6.1
6.3
74.44
71.80
u/l
0.53
234
1845
47
228
2.23
5.54
1.3
1.3
—
20.98
—
0
12
328
2951
2.85
5.54
13.4
9.2
14.74
18.02
mg/l
1.16
246
2220
113
770
1.69
4.77
4.4
6.2
1.06
1.06
inr
0.01
38
276
310
2767
2.08
4.56
9.7
8.5
3.91
3.90
mmol/l
0.21
301
2680
308
2756
2.00
4.29
9.6
8.4
139.81
139.52
mmol/l
1.91
300
2682
38
189
2.13
4.22
1.2
1.3
174.43
278.84
miu/ml
1.21
14
96
175
1368
1.56
4.05
3.2
3.6
5.96
6.23
mmol/l
1.45
167
1224
233
2657
0.63
3.85
2.8
3.2
5.52
5.57
mmol/l
0.46
215
2509
51
294
1.86
3.76
1.4
1.8
—
—
—
0
0
121
884
1.56
3.70
4.5
4.3
38.60
37.60
g/l
1.71
109
834
11
25
4.51
3.65
1.2
1.6
—
—
—
0
0
296
2686
1.67
3.00
11.9
7.3
100.45
95.61
ml/min/173m2
5.23
270
2159
6
9
6.76
2.88
1.2
2.0
—
—
—
0
0
26
463
0.53
2.60
1.2
1.5
—
—
—
0
0
15
312
0.46
2.37
1.2
1.5
—
—
—
0
0
32
187
1.78
2.30
1.3
1.7
—
—
—
0
0
6
13
4.68
2.28
1.2
1.2
—
—
—
0
0
26
442
0.56
2.23
1.2
1.6
—
—
—
0
0
12
265
0.43
2.23
1.1
1.4
—
—
—
0
0
12
265
0.43
2.23
1.1
1.4
—
—
—
0
0
32
190
1.75
2.19
1.3
1.7
—
—
—
0
0
14
288
0.46
2.16
1.1
1.5
—
—
—
0
0
215
2400
0.73
2.13
3.5
3.8
35.77
37.40
mmol/mol
2.67
200
2307
13
266
0.47
1.99
1.1
1.4
—
—
—
0
0
13
266
0.47
1.99
1.1
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
17
3.57
1.84
1.0
1.2
—
—
—
0
0
39
555
0.67
1.61
1.2
1.2
2.42
6.09
u/ml
0.89
13
237
5
15
3.37
1.53
1.0
1.3
—
—
—
0
0
9
180
0.49
1.44
1.6
1.7
—
—
—
0
0
19
112
1.74
1.38
3.5
2.0
12.36
5.48
iu/l
—
9
46
119
1004
1.28
1.37
5.1
5.5
1.22
1.21
mmol/l
0.10
96
863
49
643
0.72
1.30
1.3
1.6
1.16
1.47
mmol/l
3.02
39
580
5
20
2.52
1.15
1.0
1.4
—
—
—
0
0
0
36
0.00
1.14
0.0
1.6
—
—
—
0
0
113
1305
0.80
1.14
2.3
2.3
—
—
—
0
0
63
778
0.77
1.10
1.9
1.9
—
—
—
0
0
15
90
1.70
1.05
1.9
2.0
—
—
—
0
0
5
106
0.46
1.03
7.4
2.7
1.26
0.57
mmol/l
—
5
67
72
866
0.79
1.02
1.9
2.0
—
—
—
0
0
5
109
0.45
1.02
7.4
2.7
4.92
5.01
kpa
—
5
102
9
158
0.56
1.01
1.3
1.5
—
—
—
0
0
7
35
2.02
1.00
1.0
1.4
—
—
—
0
0
14
84
1.69
0.99
1.2
1.7
—
—
—
0
0
5
23
2.19
0.98
1.0
1.5
—
—
—
0
0
5
23
2.19
0.98
1.0
1.4
—
—
—
0
0
0
31
0.00
0.97
0.0
2.3
—
8.41
—
0
31
48
603
0.76
0.96
1.8
2.0
2.03
2.78
mg/l
3.62
39
531
47
372
1.30
0.89
2.4
2.4
511.09
232.15
ng/l
0.24
11
174
20
136
1.50
0.88
1.6
1.6
—
—
—
0
0
101
876
1.22
0.88
4.9
4.7
1.21
1.22
mmol/l
0.76
94
820
11
178
0.61
0.85
1.1
2.0
—
—
—
0
0
6
114
0.52
0.84
2.0
1.4
0.48
0.38
nmol/l
—
6
93
26
189
1.41
0.84
2.8
5.8
105.96
104.62
mmol/l
1.11
26
189
147
1617
0.84
0.83
2.7
2.9
79.46
68.84
ug/l
0.32
137
1545
261
2733
0.82
0.83
3.6
4.0
—
—
—
0
0
102
891
1.20
0.82
1.7
1.5
—
—
—
0
0
0
25
0.00
0.79
0.0
1.3
—
—
—
0
0
38
479
0.77
0.79
9.2
3.9
2.49
8.96
mg/mmol
2.37
23
318
0
27
0.00
0.77
0.0
1.0
—
1.07
—
0
10
5
24
2.10
0.75
1.0
1.4
—
—
—
0
0
31
397
0.76
0.73
1.7
1.8
—
—
—
0
0
13
84
1.57
0.73
1.8
1.8
—
—
—
0
0
26
340
0.75
0.71
1.7
2.2
2.38
2.39
mmol/l
0.27
19
296
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
29
370
0.76
0.67
1.6
1.3
29.95
24.40
iu/l
0.44
29
319
8
49
1.65
0.62
1.4
1.6
—
—
—
0
0
8
50
1.61
0.61
1.4
3.6
—
457.33
—
0
6
5
30
1.68
0.61
1.0
1.4
—
—
—
0
0
0
20
0.00
0.60
0.0
1.6
—
—
—
0
0
0
20
0.00
0.60
0.0
1.6
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
95.69
—
0
16
0
22
0.00
0.59
0.0
1.9
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
16
217
0.72
0.57
1.3
1.5
—
—
—
0
0
6
40
1.51
0.52
1.0
1.2
—
—
—
0
0
44
514
0.84
0.49
1.8
1.9
—
—
—
0
0
7
110
0.63
0.49
1.4
1.4
34.83
54.13
pmol/l
—
7
105
24
193
1.26
0.44
1.7
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
37.40
—
0
10
0
15
0.00
0.41
0.0
1.8
—
3.43
—
0
15
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
80
726
1.13
0.41
2.7
2.3
9.96
20.96
ng/l
1.53
28
265
0
17
0.00
0.40
0.0
2.0
—
—
—
0
0
0
17
0.00
0.40
0.0
2.1
—
—
—
0
0
5
34
1.48
0.40
1.0
1.6
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
35
299
1.19
0.39
1.5
1.6
1089.29
1137.87
nmol/l
0.14
27
244
5
80
0.62
0.35
1.0
1.2
—
—
—
0
0
9
125
0.71
0.35
1.6
1.5
—
—
—
0
0
6
46
1.31
0.33
1.5
1.5
78.83
164.56
ug/l
—
6
41
49
440
1.13
0.30
1.5
1.5
485.07
37864491.31
pmol/l
0.80
42
412
7
55
1.28
0.30
1.0
1.3
—
1.20
—
0
7
51
563
0.89
0.29
1.2
1.3
9.11
21.94
iu/ml
2.94
12
182
25
214
1.18
0.28
5.7
4.7
—
—
—
0
0
22
258
0.84
0.28
3.8
2.3
27.58
24.59
%
0.38
17
219
11
85
1.30
0.28
1.0
1.2
—
15.93
—
0
19
82
765
1.09
0.27
2.2
3.1
2.33
2.34
mmol/l
0.44
75
709
23
197
1.18
0.26
1.0
1.1
—
—
—
0
0
5
71
0.70
0.26
1.0
1.9
—
—
—
0
0
5
71
0.70
0.26
1.0
1.2
—
—
—
0
0
91
967
0.92
0.25
1.5
1.6
—
—
—
0
0
17
202
0.83
0.25
1.6
2.0
15.08
35.97
u/ml
1.16
17
192
70
650
1.10
0.25
1.6
1.7
0.55
0.66
mg/l
0.41
44
475
18
212
0.84
0.25
1.2
1.4
—
—
—
0
0
280
2749
1.09
0.24
6.6
4.8
1.60
2.09
mu/l
0.61
264
2648
208
2024
1.07
0.22
2.7
3.4
7.32
8.17
mm/h
0.78
197
1918
5
41
1.22
0.22
1.2
1.2
—
—
—
0
0
5
41
1.22
0.22
1.2
1.2
—
—
—
0
0
5
42
1.19
0.21
1.2
1.6
5.68
7.40
mmol/l
—
5
42
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
48
1.25
0.20
1.0
1.6
—
—
—
0
0
19
166
1.15
0.18
2.3
2.1
12.70
13.42
nmol/l
0.15
19
158
5
66
0.75
0.17
1.8
1.3
450.80
197.68
u/ml
—
5
39
5
67
0.74
0.17
1.0
1.3
—
4.71
—
0
24
22
197
1.12
0.15
3.1
2.5
—
—
—
0
0
12
140
0.85
0.15
17.4
7.5
7.01
7.05
mmol/l
0.01
12
135
87
833
1.06
0.15
1.5
1.7
100.82
96.14
pmol/l
0.31
43
476
30
326
0.91
0.14
1.6
1.3
85.93
149.45
iu/ml
1.18
14
148
10
117
0.85
0.13
1.1
1.4
—
—
—
0
0
9
108
0.83
0.13
1.2
2.1
—
—
—
0
0
13
114
1.15
0.12
1.2
1.3
—
—
—
0
0
14
157
0.89
0.11
1.4
1.2
10.81
10.62
u/l
0.02
14
129
58
606
0.95
0.11
1.8
1.8
—
—
—
0
0
10
115
0.87
0.11
1.2
1.5
1.06
1.19
g/l
—
10
109
5
46
1.09
0.09
1.0
1.0
—
—
—
0
0
6
72
0.83
0.07
1.0
1.1
—
—
—
0
0
6
73
0.82
0.07
1.7
1.2
—
—
—
0
0
9
85
1.06
0.07
1.1
1.2
—
—
—
0
0
9
86
1.05
0.07
1.1
1.2
—
—
—
0
0
8
90
0.89
0.07
3.4
7.9
0.89
0.66
%
—
8
90
8
90
0.89
0.07
3.4
7.8
2.17
1.46
%
—
8
90
9
104
0.86
0.06
1.3
1.2
1.43
2.73
ug/l
—
9
93
237
2386
0.98
0.04
5.9
4.3
14.92
14.19
pmol/l
4.75
221
2279
19
200
0.95
0.04
1.5
1.4
—
—
—
0
0
15
159
0.94
0.03
3.1
6.8
0.25
0.60
mmol/l
—
8
123
16
169
0.94
0.03
2.2
1.9
85.78
87.46
ml/min/173m2
—
9
69
81
798
1.02
0.03
1.3
1.3
0.39
2.24
u/ml
1.97
22
229
13
131
0.99
0.00
1.8
1.8
—
—
—
0
0
17
175
0.97
0.00
1.8
2.6
0.25
0.24
g/l
0.32
17
168
11
106
1.04
0.00
1.1
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
479.67
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
0.68
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
70
1.00
-0.00
2.0
2.6
23.59
23.59
mmol/l
—
7
70
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
49
1.02
-0.00
1.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
2.61
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
5
54
0.92
-0.00
1.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.04
—
0
5
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
15.34
—
0
8
0
8
0.00
-0.00
0.0
1.0
—
0.01
—
0
8
0
9
0.00
-0.00
0.0
1.7
—
7.12
—
0
9
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_FINGOLIMOD – Use of fingolimod
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).